On January 21, 2026, the National Health Regulatory Authority (NHRA) published an updated Medicine Variations Guideline for Human Medicines. The guideline, Version 3.2 (January 2026), applies to human medicines with a valid NHRA marketing authorization and sets out the regulatory requirements for managing post-approval variations, including classification, submission pathways, documentation, assessment timelines, and implementation expectations.
Details of the Update
The updated guideline applies to changes made to human medicinal products that already hold an NHRA marketing authorization and a valid license. It explains how post-approval variations are classified into Type IA, Type IB, and Type II, distinguishing minor changes from those that may significantly affect quality, safety, or efficacy.
The guideline clarifies that Type IA variations follow a “Do and Tell” approach, allowing implementation without prior approval but requiring notification within 60 working days after implementation, with the possibility of rejection if conditions are not met. Type IB variations are handled under a “Tell, Wait and Do” process, while Type II variations cover major changes requiring full assessment prior to implementation.
All variation applications must be submitted through the NHRA Adweya online system, using electronic Common Technical Document (eCTD) sequences. The guideline specifies documentation expectations, including cover letters, comparisons between current and proposed states, and country-of-origin approvals or proof, where applicable.
In terms of regulatory timelines, the NHRA states expected assessment completion periods of 7 working days for Type IA variations and 40 working days for Type IB and Type II variations. For approved changes, the guideline notes that Type IB and Type II variations should be implemented within 12 months from the date of the approval letter.
Effective Date
The Medicine Variations Guideline (Version 3.2) is effective as of January 21, 2026.
Why It Matters
This update provides clearer regulatory alignment on how post-approval changes to human medicines should be classified, submitted, reviewed, and implemented in Bahrain. By defining digital submission requirements, standardized timelines, and implementation windows, the guideline supports more efficient regulatory processing while maintaining compliance controls and minimizing administrative uncertainty for marketing authorization holders.
Who This Is Relevant For
This update is relevant for Regulatory Affairs, Quality Assurance, Compliance, CMC, and IT or regulatory operations teams responsible for managing post-approval changes and electronic submissions for human medicines authorized in Bahrain.
Next Steps
Companies should review their variation management procedures to ensure alignment with the updated NHRA requirements. This includes confirming correct variation classification, meeting Type IA notification timelines, preparing eCTD-compliant submissions through the Adweya system, and adjusting internal workflows to meet the stated assessment and implementation timelines.
As organizations adapt to these updated post-approval requirements, RegASK can support more structured and proactive compliance management. RegASK is a leading agentic AI regulatory intelligence and workflow orchestration platform that empowers global organizations in highly regulated sectors, including consumer products and life sciences, to proactively navigate complex regulatory landscapes. By combining advanced Agentic AI with experts in the loop, RegASK delivers timely predictive actionable insights and end-to-end automation, streamlining compliance processes, mitigating risks, and accelerating market access across more than 160 countries. Learn more or book a demo now.
FAQs
What is the Bahrain NHRA Medicine Variations Guideline?
It is an official guideline issued by Bahrain’s NHRA that defines how post-approval changes to authorized human medicines must be classified, submitted, reviewed, and implemented.
What types of variations are covered under the guideline?
The guideline covers Type IA, Type IB, and Type II variations, ranging from minor changes to major changes that may impact quality, safety, or efficacy.
How should variation applications be submitted to the NHRA?
All variation applications must be submitted through the NHRA Adweya online system using eCTD sequences, along with the required supporting documentation.
How can RegASK help companies manage NHRA post-approval variations?
RegASK helps teams track regulatory updates, align internal workflows with variation requirements, and manage submission of readiness through AI-driven regulatory intelligence and compliance orchestration.
Subscribe to the latest regulatory news
Curated newsletters
Relevant industry info
Access expert insights
